-
公开(公告)号：US10329282B2
公开(公告)日：2019-06-25
申请号：US15719867
申请日：2017-09-29
发明人： Yanping Zhao , Hongjun Wang , Gong Li , Yuanyuan Jiang , Xiang Li , Liying Zhou , Yanan Liu
IPC分类号： C07D405/14 , C07D413/14 , C07D403/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07D491/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D401/14 , C07D403/04 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/10 , C07D491/048 , A61K31/343 , A61K31/351 , A61K31/357 , A61K31/381 , A61K31/397 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/423 , A61K31/425 , A61K31/428 , A61K31/433 , A61K31/4412 , A61K31/4439 , A61K31/4465 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/53 , A61K31/5375 , A61K31/55 , A61K31/551 , A61K31/5513
摘要： The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).
-
公开(公告)号：US11155819B2
公开(公告)日：2021-10-26
申请号：US16644977
申请日：2018-09-07
发明人： Yanping Zhao , Hongjun Wang , Yuanyuan Jiang , Weiting Zhong , Jianmei Pang , Gong Li , Xiang Li , Yixin He , Liying Zhou , Yanan Liu
摘要： The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
-
公开(公告)号：US11939578B2
公开(公告)日：2024-03-26
申请号：US17474396
申请日：2021-09-14
发明人： Yanping Zhao , Hongjun Wang , Yuanyuan Jiang , Weiting Zhong , Jianmei Pang , Gong Li , Xiang Li , Yixin He , Liying Zhou , Yanan Liu
CPC分类号： C12N15/113 , A61P19/02 , A61P19/08 , A61P29/00 , C12N15/85 , A61K48/00 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/334 , C12N2310/335
摘要： The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
-
公开(公告)号：US11938222B2
公开(公告)日：2024-03-26
申请号：US16618756
申请日：2019-06-12
发明人： Zhaolu Zhu , Yun Wu , Di Lu , Yanping Zhao , Liying Zhou , Yanan Liu
IPC分类号： A61K9/20 , A61K31/197
CPC分类号： A61K9/2054 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K31/197
摘要： The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
-
公开(公告)号：US20220378799A1
公开(公告)日：2022-12-01
申请号：US17616571
申请日：2020-06-05
发明人： Yanping Zhao , Hongjun Wang , Bin Liu , Yuanyuan Jiang , Weiting Zhong , Huifen Xu , Honglei Zhang , Chuangchuang Huang , Nana Tian , Jing Zhao , Jing Li , Weina Liu , Liying Zhou , Yanan Liu
IPC分类号： A61K31/5377 , C07D471/04 , C07D413/14 , A61P35/00
摘要： Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.
-
公开(公告)号：US20210369621A1
公开(公告)日：2021-12-02
申请号：US16618756
申请日：2019-06-12
发明人： Zhaolu Zhu , Yun Wu , Di Lu , Yanping Zhao , Liying Zhou , Yanan Liu
IPC分类号： A61K9/20 , A61K31/197
摘要： The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the diameter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
-
7.发明授权公开(公告)号：US11414444B2
公开(公告)日：2022-08-16
申请号：US16760911
申请日：2018-10-31
发明人： Yanping Zhao , Hongjun Wang , Gong Li , Xiang Li , Yuanyuan Jiang , Kai Liu , Yeming Wang , Liying Zhou , Yanan Liu , Ning Shao , Fengping Xiao
IPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/18 , C07F9/6568
摘要： A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
-
8.发明授权公开(公告)号：US11919918B2
公开(公告)日：2024-03-05
申请号：US17826711
申请日：2022-05-27
发明人： Yanping Zhao , Hongjun Wang , Gong Li , Xiang Li , Yuanyuan Jiang , Kai Liu , Yeming Wang , Liying Zhou , Yanan Liu , Ning Shao , Fengping Xiao
IPC分类号： A61K31/506 , C07F9/6568 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/18
CPC分类号： C07F9/65685 , A61K31/506 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/18
摘要： A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
-
公开(公告)号：US11905274B2
公开(公告)日：2024-02-20
申请号：US16971702
申请日：2019-02-22
发明人： Yanping Zhao , Hongjun Wang , Gong Li , Xiang Li , Yuanyuan Jiang , Yeming Wang , Huai Huang , Liying Zhou , Yanan Liu , Ning Shao , Fengping Xiao , Zhenguang Zou
IPC分类号： C07D403/06 , C07D295/215 , C07D403/14 , C07D409/12 , C07D413/06 , C07D417/06
CPC分类号： C07D403/06 , C07D295/215 , C07D403/14 , C07D409/12 , C07D413/06 , C07D417/06
摘要： The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.
-
公开(公告)号：US20230212160A1
公开(公告)日：2023-07-06
申请号：US17926533
申请日：2021-05-20
发明人： Yanping Zhao , Bin Liu , Yuanyuan Jiang , Weiting Zhong , Huifen Xu , Hongjun Wang , Li Mao , Jingtao Li , Honglei Zhang , Chuangchuang Huang , Jing .. Li , Jing Zhao , Weina Liu , Nana Tian , Liying Zhou , Yanan Liu
IPC分类号： C07D413/14 , C07D471/04 , C07D405/14 , A61P35/02 , A61P15/08 , A61P35/00
CPC分类号： C07D413/14 , A61P15/08 , A61P35/00 , A61P35/02 , C07D405/14 , C07D471/04
摘要： Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.026 秒)
